Concord Biotech's Q1 marks return to growth: consol PAT +31% YoY to ₹58 Cr, margins expand

Concord Biotech opened FY27 with a clear rebound after a soft FY26. Q1 consolidated revenue from operations rose 26.2% YoY to ₹257.5 Cr and net profit (attributable to owners) rose ~33% to ₹58.5 Cr (₹57.7 Cr PAT for the period after a ₹0.8 Cr non-controlling loss), against ₹204.0 Cr and ₹44.1 Cr a year ago. Margins moved the right way on both lines: operating margin expanded to ~32.0% from 30.1%, and net margin to ~22.7% from 20.2%, with the print carrying no exceptional items this quarter — so the reported growth is the underlying growth, not an optics effect. EPS was ₹5.52 vs ₹4.21. The result validates management's own guidance from the Q3 FY26 concall, where it flagged FY26 as below historical averages but guided FY27 back toward historical growth with potential acceleration to a ~25% CAGR as the injectable facility, CDMO partnerships and new launches scale. A 26% YoY topline in the very first quarter sits squarely on that path. The margin recovery also aligns with management's claim that core business margins remain stable (~40% at the core level) even as new ventures carry start-up costs — the consolidated drag from those ventures is visible in the standalone-vs-consolidated gap: standalone PAT grew 43.8% YoY (to ₹61.2 Cr) versus 31% consolidated, because loss-making subsidiaries (Celliimune, acquired Apr 2, 2026; Stellon Biotech) dilute the group number. Readers seeing the higher standalone figure elsewhere should treat consolidated as the true group picture. Against the sequential quarter, revenue fell 21% and PAT 35% versus Q4 FY26 (₹326 Cr / ₹88.5 Cr), but Q4 is seasonally Concord's strongest quarter and that step-down is a seasonality artifact, not a deterioration — the YoY comparison is the signal here. Concurrent developments support the recovery read: Unit-II cleared Kenya and Uganda regulatory inspections in June, and the board declared the quarter alongside a final dividend (July 24 record date) and the 41st AGM. No formal quarterly guidance or published street consensus was available for this print; the FY26 base had seen consolidated revenue decline ~12%, so this quarter is the first concrete evidence of the guided turnaround taking hold. Management will detail the recovery on its August 3 earnings call.